Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Figure 2

Reduction in HER2 expression in HER2+target human breast cancer cell lines and HER2 expression on isolated CD14+and CD56+immune cells in the absence of trastuzumab. SK-BR-3 and BT-474 were used as targets and healthy human PBMCs were used as effectors. For the trogocytosis assay, cells were co-cultured for 60 min. Cell mixtures were subsequently stained with an APC-HER2 antibody and subjected to flow cytometry. A The trogocytosis assay was performed with an E:T cell ratio of 10:1 and various concentrations of trastuzumab (H: H0, without trastuzumab; H0.1, 0.1 μg/mL of trastuzumab; H1, 1 μg/mL of trastuzumab). SK-H1 and BT-H1; SK-BR-3 and BT-474 cells treated with 1 μg/mL of trastuzumab alone, respectively. B The trogocytosis assay was performed with an E:T cell ratio of 10:1, 100:1, and 1000:1 and 1 μg/mL of trastuzumab. C The trogocytosis assay was performed with an E:T cell ratio of 10:1, 100:1, and 1000:1 without trastuzumab treatment. *P < 0.05; **P < 0.01; ***P < 0.001 versus cancer cells only. D The trogocytosis assay was performed with isolated CD14+ or CD56+ cells in 1:2, 1:1 and 2:1 ratio with SK-BR-3 cells and without trastuzumab (H0). The level of HER2 expression on the CD14+ and CD56+ cells is shown as the percent of HER2+ cells in each condition. *P < 0.05; **P < 0.001. All figures show the mean ± SEM. Experiments were performed for a single healthy volunteer twice and similar data were obtained each time.

Back to article page